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Abstract
Background: Epstein-Barr virus (EBV) latently infects about 90% of the human population and is
associated with benign and malignant diseases of lymphoid and epithelial origin. BHRF1, an early
lytic cycle antigen, is an apoptosis suppressing member of the Bcl-2 family. In vitro studies imply that
BHRF1 is dispensable for both virus replication and transformation. However, the fact that BHRF1
is highly conserved not only in all EBV isolates studied to date but also in the analogous viruses
Herpesvirus papio and Herpesvirus pan that infect baboons and chimpanzees respectively, suggests
BHRF1 may play an important role in vivo.
Results: Herpesvirus papio BHRF1 has been shown to function in an analogous manner to EBV
BHRF1 in response to DNA damaging agents in human keratinocytes. In this study we show that
the heterologous expression of the previously uncharacterised Herpesvirus pan BHRF1 in the
human Burkitt's lymphoma cell line Ramos-BL provides similar anti-apoptotic functions to that of
EBV BHRF1 in response to apoptosis triggered by serum withdrawal, etoposide treatment and
ultraviolet (UV) radiation. We also map the amino acid changes onto the recently solved structure
of the EBV BHRF1 and reveal that these changes are unlikely to alter the 3D structure of the
protein.
Conclusions: These findings show that the functional conservation of BHRF1 extends to a
lymphoid background, suggesting that the primate virus proteins interact with cellular proteins that
are themselves highly conserved across the higher primates. Further weight is added to this
suggestion when we show that the difference in amino acid sequences map to regions on the 3D
structure of EBV BHRF1 that are unlikely to change the conformation of the protein.
Background
Apoptosis is a genetically programmed form of cell death
employed to regulate cell number, spatial organisation
and remove infected and damaged cell populations that
may compromise the integrity of the organism [1]. Aber-
rant or unscheduled apoptotic responses are thought to
contribute to various diseases including Alzheimer's dis-
ease, rheumatic diseases and neoplastic growth [2]. Induc-
tion of apoptosis in virally infected cells is a key weapon
in the immune system's arsenal against viral attack.
Many viruses have evolved multiple strategies to counter-
act host-mediated apoptosis in order to facilitate infec-
tion, replication or persistence [3,4]. Epstein-Barr virus
(EBV) a human γ-herpesvirus that latently infects the
majority of adults, was the first virus shown to influence
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with a number of benign and malignant proliferative dis-
eases, such as infectious mononucleosis, Burkitt's lym-
phoma and nasopharyngeal carcinoma [6,7]. Latent
infection of B cells in vitro leads to outgrowth of apoptosis
resistant lymphoblastoid cell lines (LCLs), which pheno-
typically resemble activated B-cells. Although B cells can
produce progeny virus, epithelial cells are also known to
be permissive for viral replication. Studies have shown
that EBV has at least two mechanisms of suppressing
apoptosis. During latent infection latent membrane pro-
tein 1 (LMP1) is the key mediator of protection. LMP1, a
CD40 mimic, up-regulates cellular Bcl-2 [8] and A20 [9]
via the NFκB pathway. The virus also encodes two struc-
tural homologues of Bcl-2: BHRF1 [10,11] and the less
well characterised and more controversial BALF1 [12,13]
which are thought to play their major roles during lytic
infection. Whilst many other viruses also have Bcl-2
homologues (v-Bcl-2s) [14], EBV and its mammalian ana-
logues appear unique in having two v-Bcl-2s.
Despite being considered dispensable for EBV replication
or cellular transformation in vitro [15,16], BHRF1 is
extremely highly conserved in distinct geographical iso-
lates of EBV [17], and its role in vivo remains unclear.
BHRF1 is thought to act in lytic cycle to delay apoptosis
during replication in terminally differentiating epithe-
lium [18]. However, some EBV-positive B-cell lympho-
mas have been found to be positive for BHRF1 transcripts
[19] and latent BHRF1 transcripts have been detected in T-
cell lymphomas [20] and in EBV-transformed tightly
latent B-cell lines in vitro [21]. Additionally, EBV BHRF1
has been shown to suppress apoptosis in lymphoid cells
in response to a range of triggers including serum depriva-
tion [11], DNA damaging agents and chemotherapeutic
drugs [22] and cytokines [23]. It is possible then, that
BHRF1 may play a role at some stage during latent infec-
tion, which warrants the study of this protein in B cells,
the target for latent infection.
Analogues of EBV are found in the higher primate species.
Herpesvirus papio (H. papio) and Herpesvirus pan (H. pan)
infect baboons and chimpanzees respectively. H. papio
encodes a BHRF1 homologue that shares 65% amino acid
identity (81% similarity) with EBV BHRF1, whilst the H.
pan BHRF1 is even more similar at 82% identity and 90%
similarity [24]. H. papio BHRF1 has been shown to confer
resistance to cisplatin induced apoptosis in human kerat-
inocytes akin to EBV BHRF1 [25], but this study represents
the first functional analysis of a primate virus BHRF1 in a
lymphoid cell background. Here we show that H. pan
BHRF1 exhibits similar anti-apoptotic activity to that of
EBV BHRF1 in the human Burkitt's lymphoma cell line
Ramos-BL in response to apoptosis induced by either
serum withdrawal, etoposide treatment and the previ-
ously untested trigger, ultraviolet radiation. These results
show that H. pan BHRF1 is biologically active in human
B-lymphocytes in vitro suggesting a conserved role for
BHRF1 during in vivo infection of B-lymphocytes.
Results
Construction of BHRF1 expression vectors and selection of 
positive clones
As the senior author has previously shown that EBV
BHRF1 suppresses apoptosis in response to serum reduc-
tion in various BL cell lines [11], we initially elected to
compare the abilities of H. pan BHRF1 and EBV BHRF1 to
regulate serum reduction induced apoptosis in the EBV
negative Ramos-BL cell line to ascertain whether the genes
are functional, as well as structural, homologues. In order
to produce expression vectors, the H. pan and EBV BHRF1
reading frames were amplified by PCR from template vec-
tors pHVPanTW4 and pDH222 respectively using primers
incorporating XhoI restriction sites. The PCR fragments
were introduced into the pCR2.1Topo® vector and the
XhoI fragment was released by restriction digestion of the
TopoBHRF1 constructs and cloned into the XhoI restric-
tion site of the pcDNA4/HisMax mammalian expression
vector (InVitrogen), which produces an N-terminal fusion
protein with 6His and Xpress epitopes.
Ramos-BL cells were electroporated with either control
vector, EBV BHRF1 or H. pan BHRF1 and cloned by limit-
ing dilution in medium containing 150 µg/ml zeocin.
There was no obvious difference in the numbers of drug
resistant clones that were produced by transfection with
the vector or either of the BHRF1 constructs. Drug resist-
ant clones were screened by RT-PCR for BHRF1 expression
and approximately 50% of the clones were shown to be
expressing detectable BHRF1. The RT-PCR profiles of two
clones each of the three transfected populations which
were selected for further analysis, are shown in Figure 1.
RT negative samples were included (lower panel) to rule
out DNA contamination of RNA samples. Expression of
the fusion proteins was confirmed by Western blot analy-
sis (not shown) and by indirect immunofluorescence
using an antibody directed against the 6His epitope (Fig-
ure 2). Some diffuse fluorescence is seen in the His C con-
trols (A and B), but this is to be expected as the fusion part
of the protein is at the amino terminus and the vector
therefore can produce a small protein containing the 6His
epitope. There is a distinctive crescent-like pattern of fluo-
rescence in clones transfected with the EBV BHRF1 (C and
D) and H. pan BHRF1 (E and F), indicative of BHRF1
expression.
Determination of sensitivity to serum withdrawal induced 
apoptosis
To determine the sensitivity of the transfected clones to
the induction of apoptosis by serum reduction, EBVPage 2 of 11
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5 and BHRF1 null vector control clones His C12 and His
C13 were seeded in medium containing either 10% or
0.1% serum and the percentage of apoptotic cells was
determined at 24-hourly intervals, using acridine orange
to distinguish between apoptotic and viable cell nuclei.
Necrotic nuclei that appeared after several days due to sec-
ondary necrosis of cells already lost by apoptosis were
excluded from the counts. Apoptotic death was also con-
firmed by DNA laddering (not shown). We found that
when maintained in medium containing 10% serum (Fig-
ure 3A), both the EBV BHRF1 clones exhibited a slight
drop in viability after 48 hours and thereafter viabilities
increased to above 90%. A similar drop in viability was
seen in the two vector clones, but after an increase at 72
hours, both clones began to show a decline in viability by
96 hours. Both the H. pan BHRF1 expressing clones, main-
tained viability above 90% throughout the 96 hours
RT-PCR analysis of transfected clonesFigure 1
RT-PCR analysis of transfected clones. The upper panel shows RT-PCR analysis of transfected clones using primers 
designed to amplify a 655 bp fragment of the BHRF1 transcripts. From left to right samples are 1) Promega kilobase ladder, 2) 
vector control clone His C12, 3) vector control clone His C13, 4) Blank 5)EBV BHRF1 clone EBV 1B, 6) EBV BHRF1 clone EBV 
3B, 7) Blank 8) H. pan BHRF1 clone Pan 4 9) H. pan BHRF1 clone Pan 5 10) Blank 11) Ramos-BL 12) negative RT control 13) 
pEBV9 14) Promega 100 bp ladder. The lower panel shows the same samples (except 13 – negative PCR control) in which the 
RT has been omitted in the RT step, to exclude DNA contamination in the RNA samples.Page 3 of 11
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showed higher rates of cell death compared to either the
EBV or H. pan BHRF1 expressing clones from 24 hours
onwards in medium containing 0.1 % serum (Figure 3B).
After 96 hours in culture, approximately 15% viability was
observable in the BHRF1 null vector controls whilst the
viability of the BHRF1 clones ranges from 35 to 49%.
Clone EBV IB was the most resistant to apoptosis induced
by serum deprivation with 49% viability after 96 hours.
Two-way ANOVA and Tukey's pairwise analysis of arcsine
transformed data showed that at all time points from 48
hours onwards there were significant differences (p <
0.001) between the BHRF1 expressing clones and the vec-
tor control clones, but not between the Pan and EBV
BHRF1 clones, except at 96 hours when clone EBV 1B
showed significantly higher viability than all other clones
(eg p = 0.0001 when compared to EBV 3B). Therefore our
data indicates that 0.1% serum is sub-optimal for survival
of Ramos-BL since a high degree of apoptotic cells are
observable at this concentration. Clearly however, both
EBV and H. pan BHRF1 expression were able to delay the
apoptotic response, and thus promote the survival of
these cells which would otherwise undergo apoptosis.
Determination of sensitivity to etoposide induced 
apoptosis
We then investigated whether or not the proteins could
regulate apoptosis induced by the DNA damaging agent
etoposide. The transfected clones were seeded in medium
containing either no etoposide or 200 ng/ml etoposide.
The percentage of viable versus apoptotic cells was deter-
mined every 24 hours by acridine orange fluorescence. We
found that, in the absence of etoposide, viability was
maintained at above 90% in all clones (Figure 4A). In the
presence of etoposide (Figure 4B), both the control clones
showed a steady decline in viability from 24 hours
onwards, with clone His C13 maintaining higher viability
than His C12, whilst the BHRF1 clones remained viable
for 48 hours before starting to show a decline in viability.
Two way ANOVA and Tukey's pairwise comparisons of
arcsine transformed data showed that the differences
between the control and BHRF1 clones were significantly
different from 24 hours onwards. Whilst clone His C13
was significantly different to the BHRF1 clones at all time
points, it was also significantly different to His C12 at the
72 (p = 0.359) and 96 (p = 0.002) hour time points. There
were no significant differences between the EBV and Pan
BHRF1 clones.
Determination of sensitivity to ultraviolet induced 
apoptosis
Ultraviolet radiation has been shown to induce apoptosis
in other cell lines within a 24 hour period. Having first
determined the UV conditions necessary to induced apop-
tosis in the parent cell line, we then exposed the
transfected clones to UV radiation at 30 Jm-2. Acridine
orange counts were taken after 24 hours and the results
are shown in figure 5. Statistical analysis was performed
on both the transformed and untransformed data. The
untransformed data is shown in Figure 4, as the error bars
were so small in the transformed data that they were not
visible. The results are highly significant with p <
0.000001.
Mapping the amino acid changes on to the 3D structure
During the course of this study, the structure of BHRF1
was solved [26]. Using RasMol, v2.6, the freely available
molecular visualisation software created by Roger Sayle,
Detection of BHRF-1 fusion protein by indirect immunoflu rescenceFigure 2
Detection of BHRF-1 fusion protein by indirect 
immunofluorescence. Cell smears were incubated with 
Clone His-1 monoclonal anti-polyhistidine antibody followed 
by FITC-conjugated goat anti-mouse antibody, viewed by flu-
orescence microscopy and photographed at 15× magnifica-
tion (1.27 s exposure) using a digital camera. Key A – His 
C12; B – His C13; C – EBV 1B; D – EBV 3B; E – Pan 4 and F 
– Pan 5.Page 4 of 11
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BMC Microbiology 2005, 5:6 http://www.biomedcentral.com/1471-2180/5/6Determination of apoptosis levels in reduced serum conditionsFigu e 3
Determination of apoptosis levels in reduced serum conditions. The percentage viability of EBV and H. pan BHRF1 
Ramos-BL transfectants compared to vector controls in medium containing A) 10% serum or B) 0.1% serum over a 4 day 
period. The % viability was determined daily by acridine orange fluorescence. The data plotted are the means three experi-
ments carried out in triplicate ± standard error. Statistical analysis was performed using ANOVA and Tukey's pairwise com-
parison on data normalised by arcsine transformation.
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Determination of apoptosis levels in etoposide treated cells. The percentage viability of EBV and H. pan BHRF1 
Ramos-BL transfectants compared to vector controls in medium containing A) DMSO control or B) 200 ng/ml etoposide over 
a 4 day period. The % viability was determined daily by acridine orange fluorescence. The data plotted are the means three 
experiments carried out in triplicate ± standard error. Statistical analysis was performed using ANOVA and Tukey's pairwise 
comparison on data normalised by arcsine transformation
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regions where the EBV and H. pan proteins differ, as
shown in Figure 6A. Non-conservative changes, shown in
yellow, tend to be found at the end of helices, whereas
conservative replacements tend to be within the helices.
There are changes within the known functional BH
domains (shown in red). The aligned primary amino acid
sequences, with the BH domains and changes highlighted
using the same colour scheme are shown in Figure 6B.
Discussion
In this study we present evidence that the BHRF1 protein
encoded by H. pan is functionally homologous to the
analogous protein in the EBV in human B cells. BHRF1 is
one of two Bcl-2 homologues encoded by EBV. Previously
the EBV BHRF1 protein has been shown to protect trans-
fected B-cells from apoptosis [11] and delay the differen-
tiation of epithelial cells in vitro [18]. The primate virus
analogues of BHRF1 have now been cloned by us and oth-
ers [24,25] and have been shown to be highly homolo-
gous in their primary structure both at the DNA and
protein level. BHRF1 is normally expressed at high levels
in during lytic replication in epithelial cells and the first
functional studies of a primate BHRF1, namely the
baboon virus BHRF1, were carried out in a keratinocyte
system. Whilst a role for BHRF1 during latent infection
Determination of apoptosis levels in UV irradiated cellsFigu e 5
Determination of apoptosis levels in UV irradiated cells. The effect of 30 Jm-2 UV irradiation (solid bars) on EBV 
BHRF1 and H. pan BHRF1 transfected Ramos-BL clones compared to vector controls. Cell viability was assayed after 24 hours 
by acridine orange fluorescence. The data plotted are the means three experiments carried out in triplicate ± standard error. 
Statistical analysis was performed using ANOVA and Tukey's pairwise comparison on data normalised by arcsine 
transformation
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BMC Microbiology 2005, 5:6 http://www.biomedcentral.com/1471-2180/5/6Mapping of amino acid changes in H. pan BHRF1 on the EBV BHRF1 structureFigure 6
Mapping of amino acid changes in H. pan BHRF1 on the EBV BHRF1 structure. The structure of the first 160 amino 
acids of EBV BHRF1 was visualised by importing the structural data file (1q59.pdb) into RasMol v2.6, which converts the struc-
tural data into a 3 D image (Figure 6A) Using the RasMol edit commands we have highlighted the BH domains in red, whilst the 
remainder of the protein is shown in dark blue. Conservative replacements in the H. pan protein are highlighted in light blue 
and non-conservative replacements are shown in yellow. For comparison the aligned amino acid sequenced are shown in Fig-
ure 6B, using the same colour coding as in Figure 6A.
  A 
  B 
EBV      MAYSTREILLALCIRDSRVHGNGTLHPVLELAARETPLRL
H.pan    MAYSTRDILLALCMRDSYVHGNGSLHPVLELAARETPPRV 
EBV     SPEDTVVLRYHVLLEEIIERNSETFTETWNRFITHTEHVD
H.pan    SPEDTVVLRLHLLLEEVIQQNAESFTNTWETFITNAEHVD
EBV      LDFNSVFLEIFHRGDPSLGRALAWMAWCMHACRTLCCNQS
H.pan    LDFAAVFEDIFHRGDPSLGRALAWLAWCMHACRTLCRNQN
EBV      TPYYVVDLSVRGMLEASEGLDGWIHQQGGWSTLIEDNIPG
H.pan    TPYYVVDLSVRGMLEASEGLDAWIHQQGGWTGLIRSDSLGPage 8 of 11
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transcripts are found in certain lymphoid malignancies
and that BHRF1 can suppress apoptosis in lymphoid cells
suggests that BHRF1 has the potential to contribute to
malignant transformation. Whilst infection of B cells is
largely latent, lytic replication in B cells also plays an
important role in EBV's lifecycle by providing virus to re-
infect epithelial cells, ensuring the continued shedding of
virus in the oropharynx. We therefore decided to investi-
gate whether the functional homology extended to a lym-
phoid cell background by comparing EBV BHRF1 with the
previously uncharacterised BHRF1 from H. pan. We used
3 triggers known to induce apoptosis at differing rates.
Serum withdrawal is a slow trigger, with low levels of
apoptosis for 48 hours followed by a precipitous drop in
viability. The kinetics of etoposide activity are very differ-
ent with a steady decline in viabilty over the 4 day period,
whilst UV irradiation (never previously reported for
BHRF1) induces apoptosis within hours. The EBV and H.
pan BHRF1s afforded significant protection against the
induction of apoptosis by all three triggers, compared to
the vector controls. There was no statistical difference
between the EBV and H. pan BHRF1s, (except for clone
EBV1B at 96 hours in 0.1% serum), suggesting that H. pan
BHRF1 is indeed a true functional homologue of EBV
BHRF1. The difference between clone EBV1B and the
other BHRF1 clones at 96 hours in low serum could pos-
sibly be attributed to slightly higher levels of BHRF-1
expression in this clone, although it is difficult to quantify
absolute expression levels from the fluorescence images
shown in Figure 2. Clone His C13 maintained higher via-
bility than clone His C12 against all three triggers and
when exposed to etoposide this is statistically significant
from 72 hours onwards. This possibly reflects genetic
changes accumulated by the clones during selection and
passage and highlights the importance of including more
than one clone in assays such as these.
When one looks more closely at the regions of the protein
that differ between the human and chimpanzee viruses
(Figure 6), it is perhaps not surprising that the two pro-
teins are functional homologues, despite the changes in
the amino acid sequence. The non-conservative changes
are almost always at the end of a helix where they are least
likely to disrupt the overall structure of the protein, whilst
the conservative changes are mainly within the helices or
loops. Notably there are some changes within the BH
domains, known to be critical for the function of Bcl-2
family proteins, which are clearly tolerated in terms of
conservation of function. None of the observed changes
are likely to significantly alter the conformation of the
protein, highlighting the fact that functional conservation
of BHRF1 is subject to 3D structural constraints. These
observations emphasise the importance of combining
structural information with homology studies such as this
one to identify regions of the protein that need to be con-
served to retain structural integrity. That the two proteins
appear to be so similar at the 3D level implies they prob-
ably interact with cellular proteins that are themselves
highly conserved in the two species. There are only a few
reports of proteins known to interact with BHRF1, includ-
ing PRA1 [27] and although some studies have shown
interactions with several Bcl-2 family proteins [28,29], the
reported differences in the 3D structures of BHRF1 and
Bcl-2 (namely the lack of a binding groove for pro-apop-
totic Bcl-2 family members) [26] suggests that the anti-
apoptotic activity of BHRF1 does not exactly parallel that
of Bcl-2. This warrants further study into the viral and cel-
lular proteins which interact with BHRF1, not only to
yield more insight into the interplay between virus and
host, but also to further our knowledge of the fundamen-
tal mechanisms of apoptosis.
Conclusions
Our results are the first demonstration of functional
homology between a primate BHRF1 (H. pan) and EBV
BHRF1 in a human lymphoid cell background. Both pro-
teins protect against apoptosis induced by two previously
described triggers and also a new trigger, UV radiation,
against which BHRF1 has never been reported to provide
protection. Comparison of the EBV and H. pan proteins at
the 3D structural level reveals that none of the changes is
likely to significantly alter the structure of the protein.
Methods
Construction of expression vectors
The 573 bp coding sequences of EBV BHRF1 and H.
panBHRF1 were amplified by PCR from pDH222 [11] and
pHVPanTW4 [24] respectively using primers which incor-
porated XhoI sites flanking the translational start and stop
codons. We used Promega's PCR mastermix with 50 pmol
each primer. The sequence of the forward primer was
TTGCAGCTCGAGATGGCCTATTC and the reverse primer
sequence was GAAAATCTCGAGATTAGTGTCTTCC. The
PCR parameters were 35 cycles of 95°C (30 sec), 55°C
(30 sec) and 72°C (60 sec). The PCR products were intro-
duced by Topo TA cloning into pCR2.1-Topo® (Invitro-
gen) and the XhoI fragments were released by digestion
with XhoI and cloned into the Xho1 site of pcDNA4/His-
MaxC (Invitrogen). The plasmids were sequenced to verify
that the sequences had joined in frame and contained no
PCR induced errors.
Transfection of Ramos-BL cells
6 × 106 Ramos-BL cells were independently transfected
with 20 µg endotoxin-free EBV BHRF1, H. panBHRF-1 or
vector control constructs (pEBV9, pPan4 and pcDNA4/
HisMax respectively) by electroporation in a BioRaD Gene
Pulser II at 0.45 kV, 125 µF. The cells were seeded in 96-
well plates at a density of 5 × 104 cells/ well in RPMI 1640Page 9 of 11
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(HyClone) 2 mM L-glutamine (Sigma) 0.4% gentamycin
(Sigma) and 200 µg/ml Zeocin (Invitrogen). Wells show-
ing outgrowth of drug resistant cells were cloned by limit-
ing dilution and clones were expanded into 2 ml cultures
and maintained in medium containing 150 µg/ml Zeocin.
All cultures were fed twice weekly by replacing 90% of the
culture with fresh medium.
RT-PCR
Total RNA was purified from 5 × 106 cells using the RNA
Safekit (Q Biogene) according to manufacturers instruc-
tions. Reverse transcription of 100 ng RNA with oligo dT
primer using the Improm II kit (Promega) in a total vol-
ume of 20 µl according to manufacturer's instructions was
followed by PCR (parameters as above) using 5 µl of the
template cDNA and 50 pmols each of the forward and
reverse primers CTGTACGACGATGACGATAAG and
GTGTCTTCCTCTGGAGATA respectively, to amplify a 655
bp product.
Indirect immunofluorescence
Cells were suspended in PBS and spotted onto multiwell
glass slides and air dried for 60 minutes. Slides were fixed
for 20 minutes in methanol at -20°C followed by 5
minutes in acetone at -20°C. The cell spots were rehy-
drated in 20% normal rabbit serum (in PBS) for 20 min-
utes then incubated with a 1 in 500 dilution of the
monoclonal anti-poly histidine antibody (Clone HIS-1,
Sigma-Aldrich) for 1.5 hours at room temp. After three 5
minute washes with PBS, the cells were incubated with a
1 in 50 dilution of FITC goat anti-mouse IgG (Biomeda)
for 1 hour at room temp. Thereafter the slides were
washed thrice in PBS, a drop of DABCO was added and
coverslips were placed over the cell spots. The cells were
viewed with by fluorescence microscopy and photo-
graphed with a Leica digital camera using a 1.27 sec expo-
sure time and 15× magnification.
Apoptosis assays
For the serum reduction assay cells were washed 3 times
in PBS and then 0.5 × 106 cells (BHRF1 or vector clones)
were seeded in either medium containing 10% serum or
0.1% serum and the percentage of viable versus apoptotic
cells was determined by acridine orange flourescence at 24
hour intervals. For the etoposide assays, 0.5 × 106 cells
(washed 3 times) were seeded in either routine medium
containing DMSO (equivalent to the volume added to the
etoposide samples) or medium containing 200 ng/ml
etoposide (diluted from a 1 mg/ml solution in DMSO)
and the % of apoptotic cells versus viable cells was deter-
mined every 24 hours by acridine orange fluorescence. For
the UV induction assays, 1 × 106 cells in 10 ml of medium
were placed in a Petri dish and exposed to 30 Jm-2 UV. The
cells were then pelleted by centrifugation and resus-
pended at 2 × 105cells/ml in medium and returned to cul-
ture flasks.
Each clone was tested in triplicate and each experiment
was repeated 3 times.
Acridine orange fluorescence
10 µl acridine orange (100 µg/ml) was added to 100 µl of
cell culture containing the individual clones. At least 200
cells were counted using a haemocytometer at 15 × mag-
nification and the number of viable versus apoptotic cells
in the population noted.
List of abbreviations
EBV – Epstein Barr virus, H. pan – Herpesvirus pan, PBS
phosphate buffered saline, PCR – polymerase chain reac-
tion, UV – ultraviolet, v-Bcl-2 – viral Bcl-2 homologue
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